ClinicalTrials.gg
CompletedNCT00511147Updated Jun 12, 2017Results posted

IGIV Study for Chronic ITP Patients Ages 3-70

A Phase 3 interventional study of IGIV3I Grifols 10% in Idiopathic Thrombocytopenic Purpura, sponsored by Grifols Biologicals, LLC. Completed at 45 sites in 4 countries. Open to participants aged 3 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-12.

Sponsored by Grifols Biologicals, LLC (part of Grifols) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
3 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic — 3 open to participants now, 3 under way, 1 of them phase 3. Immunoglobulins, Intravenous · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
5th of 13
64 · median 40
Started
2008
the only one that year
Phase 3
9 of 13
1 open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
Grifols Biologicals, LLC

Among the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, this one is the 5th largest by enrollment, is the only one that started in 2008, is one of 9 in phase 3, and was the 7th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

3 of the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

Idiopathic (immune) thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by platelet destruction and thrombocytopenia (peripheral blood platelet count \< 150 x 10\^9/L). IVIG therapy is useful in patients in whom the platelet count has to be raised either due to bleeding signs, or where bleeding is predicted (e.g., surgery or parturition). The primary goal of treatment is to maintain the platelet count at a hemostatic level. This study will test the safety and efficacy of IGIV3I Grifols 10% in the treatment of patients with chronic ITP.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura

Keywords

  • IVIG
  • ITP
04

Who can participate

Ages eligible
3 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of chronic ITP
  • count ≤ 20 x 10\^9/L
  • When administered at any time within 3 weeks before screening visit, the subject must have completed at least 3 weeks (21 days) of therapy at a stable and constant dose and schedule prior to screening visit
  • When administered azathioprine () at any time within 3 months before screening visit, the subject must have received a stable dose and schedule for at least 3 months prior to screening visit
  • When administered vinca alkaloids (eg., vincristine) at any time within 2 weeks before screening visit, the subject must have received a stable dose and schedule for at least 2 weeks prior to screening visit
  • When administered attenuated androgens (eg, danazol) at any time within 8 weeks before screening visit, the subject must have received a stable dose and schedule for at least 8 weeks prior to screening visit.
  • Females of must test negative for pregnancy

Key Exclusion Criteria:

  • History or clinical evidence of medical conditions (other than ITP) felt to be the underlying cause of the thrombocytopenia
  • Diagnosis of secondary immune thrombocytopenia
  • History of severe (eg, anaphylactic) reactions to blood or any blood- derived product
  • History of intolerance to any component of the IP, such as sorbitol
  • Suffering serious and/or life-threatening hemorrhage/bleeding defined as:
  • Any intracranial or central nervous system bleeding
  • Any hemorrhagic event in which the subject is at risk of death at the time of the event
  • Females who are pregnant or nursing an infant child
  • Known to have immunoglobulin A (IgA) deficiency
  • Known to abuse alcohol, opiates, psychotropic agents or other chemicals or drugs, or has done so within 12 months of the screening visit
  • Documented diagnosis of thrombotic complications to polyclonal IVIG therapy in the past
  • Unstable or uncontrolled disease, or condition, related to, or impacting, cardiac function: unstable angina, congestive heart failure, uncontrolled arterial hypertension
  • Is anemic ( \< 9 g/dL)
  • Renal impairment (ie, serum creatinine > 1.5 x [ULN])
  • or alanine aminotransferase levels > 2.5 x ULN
  • Known to have a positive test for either or (HIV 1/2)
  • Splenectomy within the prior 8 weeks to the screening visit
  • currently receiving any treatment for ITP except corticosteroids, azathioprine, vinca alkaloids or danazol
  • Received an immune serum globulin (ISG) product within the prior 3 weeks (21 days) to the screening visit
  • Received any alkylating agent (eg, cyclophosphamide) within 5 weeks prior to the screening visit
  • Received rituximab within the prior 3 months to the screening visit
  • Was currently receiving, or received, any therapeutic drug or device that was not approved by a Regulatory Authority (US or Canadian) for any indication within the prior 12 weeks to the screening visit
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    IGIV3I Grifols 10% (All Subjects)

    All subjects with Chronic ITP

    Biological: IGIV3I Grifols 10%

Interventions

  • IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.

    Also known as: Intravenous immunoglobulin

06

What researchers measure

Primary outcomes

  1. Response Rate

    Defined by the percentage of treated patients in whom platelet counts increase from ≤ 20 x 10\^9/L to ≥ 50 x 10\^9/L by Day 8 ± 1 \[where the day of the first infusion is Day 1\]

    Time frame: 8 days

Secondary outcomes

  1. Time to Platelet Count Recovery

    Defined by the number of days elapsed from Day 1 (the day of the first infusion of the IP) to the day when the platelet count is first known to be ≥ 50 x 10\^9/L at any moment during the clinical follow-up period ending on Day 30 ± 1

    Time frame: 30 days

  2. Duration of Response

    Defined by the number of consecutive days for which the platelet count remains ≥ 50 x 10\^9/L at any moment during the clinical follow-up period ending on Day 30 ± 1.

    Time frame: 30 days

  3. Regression of Hemorrhage/Bleedings

    Defined by the percentage of treated patients with hemorrhage/bleedings at Day 1 (i.e., the day of the first infusion, pre-infusion) who improve their diathesis during the clinical follow-up period ending on Day 15 ± 1.

    Time frame: 15 days

07

Results

Posted May 5, 2017

Participant flow

Participant flow — Overall Study
MilestoneIGIV3I Grifols 10% (All Subjects)
Started64
Completed57
Not completed7
Withdrew: Withdrawal by subject1
Withdrew: Disease progression5
Withdrew: Required platelet transfusion1

Outcome measures

PrimaryResponse Rate

Defined by the percentage of treated patients in whom platelet counts increase from ≤ 20 x 10\^9/L to ≥ 50 x 10\^9/L by Day 8 ± 1 \[where the day of the first infusion is Day 1\]

Time frame:
8 days
Reported as:
Number · percentage of responders
Response Rate
percentage of respondersIGIV3I Grifols 10% (All Subjects)
Response Rate81.3
SecondaryTime to Platelet Count Recovery

Defined by the number of days elapsed from Day 1 (the day of the first infusion of the IP) to the day when the platelet count is first known to be ≥ 50 x 10\^9/L at any moment during the clinical follow-up period ending on Day 30 ± 1

Time frame:
30 days
Reported as:
Mean · days
Time to Platelet Count Recovery
daysIGIV3I Grifols 10% (All Subjects)
Time to Platelet Count Recovery1.7 ± 0.85
SecondaryDuration of Response

Defined by the number of consecutive days for which the platelet count remains ≥ 50 x 10\^9/L at any moment during the clinical follow-up period ending on Day 30 ± 1.

Time frame:
30 days
Reported as:
Mean · days
Duration of Response
daysIGIV3I Grifols 10% (All Subjects)
Duration of Response10.8 ± 7.69
SecondaryRegression of Hemorrhage/Bleedings

Defined by the percentage of treated patients with hemorrhage/bleedings at Day 1 (i.e., the day of the first infusion, pre-infusion) who improve their diathesis during the clinical follow-up period ending on Day 15 ± 1.

Time frame:
15 days
Reported as:
Number · percent of subjects with regression
Regression of Hemorrhage/Bleedings
percent of subjects with regressionIGIV3I Grifols 10% (All Subjects)
Regression of Hemorrhage/Bleedings90.9

Adverse events

Collected over 30 days follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV3I Grifols 10% (All Subjects)0/64 (0%)4/64 (6.3%)59/64 (92.2%)
Most frequent serious events
Most frequent serious events
EventIGIV3I Grifols 10% (All Subjects)
HeadacheNervous system disorders2/64
meningitis asepticInfections and infestations1/64
soft tissue inflammationGeneral disorders1/64
Most frequent other events
Showing 10 of 14
Most frequent other events
EventIGIV3I Grifols 10% (All Subjects)
HeadacheNervous system disorders41/64
NauseaGastrointestinal disorders13/64
PyrexiaGeneral disorders13/64
ChillsGeneral disorders12/64
VomitingGastrointestinal disorders9/64
ContusionInjury, poisoning and procedural complications8/64
Body temperature increasedInvestigations7/64
Back painMusculoskeletal and connective tissue disorders7/64
HypotensionVascular disorders6/64
DizzinessNervous system disorders5/64

Baseline characteristics

Age, Continuous
Age, Continuous(years)IGIV3I Grifols 10% (All Subjects)
Mean33.4 ± 18.50
Sex: Female, Male
Sex: Female, Male(Participants)IGIV3I Grifols 10% (All Subjects)
Female43
Male21
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IGIV3I Grifols 10% (All Subjects)
Asian32
Black/African American2
Hispanic/Latino6
White24
08

Study locations

45 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85061, United States
  • Scottsdale Medical Specialists
    Scottsdale, Arizona 85258, United States
  • Arizona Oncology Associates
    Tucson, Arizona 85745, United States
  • Scripps Cancer Center
    La Jolla, California 92037, United States
  • Kenmar Research Institute, LLC
    Los Angeles, California 90057, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Cancer Center of Central Connecticut
    Southington, Connecticut 06489, United States
  • Georgetown University
    Washington, D.C., District of Columbia 20007, United States
  • VA Medical Center
    Washington, D.C., District of Columbia 20422, United States
  • Halifax Health Medical Center
    Daytona Beach, Florida 32114, United States
  • Hematology Oncology Associates
    Lake Worth, Florida 33461, United States
  • Lakeland Regional Cancer Center
    Tampa, Florida 33607-6307, United States
  • St. Joseph's Children's Hospital of Tampa
    Tampa, Florida 33607-6307, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Emory University School of Medicine Winship Cancer Center
    Atlanta, Georgia 30322, United States
  • Advocate Hope Children's Hospital
    Oak Lawn, Illinois 60453, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • Children's Hospital
    New Orleans, Louisiana 70118, United States
  • Kalamazoo Hematology & Oncology
    Kalamazoo, Michigan 49048, United States
  • CTO Breslin Cancer Center/MSU/Great Lakes Cancer Institute
    Lansing, Michigan 48910, United States
  • University of Mississippi
    Jackson, Mississippi 39216, United States
  • Capital Comprehensive Cancer Care Clinic
    Jefferson City, Missouri 65109, United States
  • UMDNJ-RWJ Medical School
    New Brunswick, New Jersey 08901, United States
  • Mt. Sinai Medical Center
    New York, New York 10029, United States
  • Children's Hospital, University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Western Pennsylvannia Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Baptist Cancer Center
    Beaumont, Texas 77705, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • Tyler Hematology Oncology PA
    Tyler, Texas 75701, United States
  • MCV Hospital
    Richmond, Virginia 23298, United States
  • University of Alberta
    Edmonton, Alberta T6G 2H7, Canada
  • St. Joseph's Healthcare
    Hamilton, Ontario L8N4A6, Canada
  • Narayana Hrudayalaya Hospitals
    Karnataka, Bangalore 560099, India
  • Shalby Hospitals
    Ahmedabad, 380015, India
  • St. John's Medical College Hospital
    Bangalore, 560034, India
  • Artemis Health Institute
    Haryana, 122001, India
  • Netaji Subhash Chandra Bose Cancer Research Institute
    Kolkata, 700 016, India
  • Christian Medical College
    Ludhiana, 141008, India
  • Kodlikeri Hospital
    Maharashtra, 431001, India
  • Grant Medical Foundation, Ruby Hall Clinic
    Pune, 411001, India
  • Sahyadri Specialty Hospital
    Pune, 411004, India
  • Apple Hospital
    Surat, 395002, India
  • Christian Medical College
    Vellore, 632004, India
  • Fundacion de Investigacion de Diego
    San Juan, 00927, Puerto Rico
09

References and documents

Publications

  • Apte S, Navarro-Puerto J, Damodar S, Ramanan V, John J, Kato G, Ross C, Shah C, Torres M, Fu C', Rucker K, Pinciaro P, Barrera G, Aragones ME, Ayguasanosa J. Safety and efficacy of intravenous immunoglobulin (Flebogamma(R) 10% DIF) in patients with immune thrombocytopenic purpura. Immunotherapy. 2019 Feb;11(2):81-89. doi: 10.2217/imt-2018-0165. Epub 2018 Nov 30. PubMed 30499734 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2007
First posted
Aug 3, 2007
Start
May 2008
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
May 5, 2017
Last update
Jun 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00511147
Responsible party
Sponsor
First posted
Aug 3, 2007
Start date
May 2008
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
May 5, 2017
Last update
Jun 12, 2017

Study contacts

Ali Khojasteh, MD
principal investigator · Capitol Comprehensive Cancer Care Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion